Results 11 to 20 of about 2,498 (139)
Cabergoline therapy for Macroprolactinoma during pregnancy: A case report [PDF]
BMC Research Notes, 2012 Background We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to Bromocriptine. Case presentation We report the case of a 31 year old lady who presented to us with uncontrolled hyperprolactinemia ...
Shahzad Hira +2 more
doaj +2 more sources
Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients [PDF]
Gazi Medical JournalObjective: To investigate the efficacy of the dopamine agonist cabergoline in uncontrolled acromegaly despite long-acting somatostatin analog (SSA). Methods: Thirty-five patients with acromegaly who were followed up in the department of endocrinology ...
Mehmet Muhittin Yalçın +13 more
doaj +2 more sources
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
Indian Journal of Endocrinology and Metabolism, 2017 Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking ...
Shruti Khare +6 more
doaj +2 more sources
Cabergoline-induced tricuspid regurgitation: Case report and review of literature
Indian Journal of Endocrinology and Metabolism, 2011 The increased risk of cardiac valve disease in patients treated for Parkinson′s disease with cabergoline has raised concerns about the safety of treatment with ergot-derived dopamine agonists in patients with endocrine diseases, especially prolactinoma ...
Mohammad Hayat Bhat +4 more
doaj +2 more sources
Therapeutics and Clinical Risk Management, 2016 Doua AlSaad,1 Samah ElSalem,1 Palli Valapila Abdulrouf,1 Binny Thomas,1,2 Tayseer Alsaad,3 Afif Ahmed,1 Moza AlHail4 1Department of Pharmacy, Women’s Hospital, Hamad Medical Corporation, Doha, Qatar; 2Department of Pharmacy and Life Sciences ...
AlSaad D +6 more
doaj +1 more source
Cabergoline-induced mania in a patient of pituitary microadenoma
Indian Journal of Psychological Medicine, 2017 Cabergoline, a dopamine agonist agent, is commonly used in the treatment of hyperprolactinemia, Parkinson's disease, restless leg syndrome, and antipsychotic-induced prolactin elevation.
Satyakam Mohapatra, Mihir Ranjan Nayak
doaj +2 more sources
Long-term Effects of Cabergoline and Levodopa in Japanese Patients with Early Parkinson’s Disease: A 5-Year Prospective Study [PDF]
, 2012 Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications.
Utsumi, Hiroya +1 more
core +1 more source
BMC Pharmacology and Toxicology, 2021 Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby +6 more
doaj +1 more source
A Practical Synthesis of Cabergoline [PDF]
The Journal of Organic Chemistry, 2002 Cabergoline is an N-acylurea derived from 9,10-dihydrolysergic acid, which is a potent prolactin inhibitor. It is marketed by Pharmacia as Dostinex for the treatment of hyperprolactinemia and is currently under active development for the treatment of a variety of CNS disorders.
Scott W, Ashford +3 more
openaire +2 more sources
Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment
Journal of Feline Medicine and Surgery Open Reports, 2021 Case summary A 7-year-old spayed female domestic shorthair cat weighing 5 kg was referred with polyuria, polydipsia, lethargy, abdominal distension and dermatologic abnormalities.
Diego D Miceli +4 more
doaj +1 more source